Tri-Institutional Tuberculosis Research Advancement Center (TRAC)

三机构结核病研究促进中心 (TRAC)

• 批准号: 10675723
• 负责人: Daniel W Fitzgerald
• 金额: $ 101.07万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10675723
• 关键词: Address; Animal Model; Area; Award; Basic Science; Biochemistry; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communication; Development; Discipline; Educational workshop; Environment; Faculty; Fostering; Funding; Genetic; Goals; Haiti; Human Genetics; Immunology; Institution; Interdisciplinary Study; International; Leadership; Libraries; Maps; Medicine; Memorial Sloan-Kettering Cancer Center; Mentorship; Microbiology; Morbidity - disease rate; National Institute of Allergy and Infectious Disease; New York City; Postdoctoral Fellow; Prevention; Program Evaluation; Research; Research Personnel; Research Priority; Research Project Grants; Research Training; Resources; Sampling; Science; Scientist; Site; Strategic Planning; Structure; Tanzania; Technical Expertise; Technology; Translational Research; Travel; Tuberculosis; Underrepresented Minority; United States National Institutes of Health; Universities; Woman; biobank; career; clinical research site; drug discovery; experience; implementation science; improved; innovation; member; mortality; multidisciplinary; mycobacterial; organizational structure; programs; recruit; symposium; tuberculosis diagnostics

Overall Abstract: We propose a Tri-Institutional Tuberculosis (TB) Research Advancement Center (TRAC) at Weill Cornell Medicine, Memorial Sloan-Kettering Cancer Center and Rockefeller University. The three institutions are adjacent to each other on a Tri-Institutional (Tri-I) campus in New York City. The purpose of the proposed Tri-I TRAC is to pool the expertise and resources of an outstanding team of 20 senior TB investigators at the three institutions to expand the number of investigators in the field of TB research and to promote innovative multidisciplinary TB research. The senior investigators have diverse expertise spanning biochemistry, basic microbiology, mycobacterial genetics, human genetics and immunology, drug discovery, international clinical trials, and implementation science. A major focus will be supporting New Investigators (NIs), who we define as senior post-doctoral fellows or junior faculty members who seek an academic career and have not yet received an R01. We also will recruit New to TB (N2TB) Investigators, who are R01 experienced investigators in other scientific disciplines who bring their expertise to study TB. The TRAC will have four Cores. The Administrative Core will provide leadership, financial oversight, communication, and program evaluation. A Developmental Core will fund 6 Developmental Project Awards annually of $50,000 each to support NIs and N2TB investigators. Institutional support from Weill Cornell Medicine will fund two of these awards each year which will be designated for under-represented minorities and women scientists. The Clinical Core will build upon long-standing collaborations primarily in Haiti and also in Tanzania. The Basic and Clinical Science Cores will provide NI and N2TB recipients of Developmental Project Awards mentorship, technical expertise, and scientific resources unique to TB research including access to TB animal models, genetically modified mycobacterial libraries, and biobanked clinical samples. The Basic and Clinical Science Cores will also facilitate sharing of technology and resources between senior TB investigators in order to initiate new lines of collaborative translational TB research. Other activities including an annual symposium, a technology workshop, and travel to international TB clinical sites will bolster the pipeline of new TB investigators and generate an environment conducive to multidisciplinary collaboration. There will be no overlap with other NIH research grants, centers, or institutional cores. The TRAC will leverage these existing resources and synergistically expand the number of TB investigators and foster new innovative lines of collaboration. Our goal over 5 years is to have 25 NIs successfully compete for a TB related NIH R01 and transition to independence and to attract at least 5 N2TB investigators to TB science. Half will be women and at least 20% underrepresented minorities. We will also initiate new lines of collaborative translational research to address the five NIAID priorities in TB science with the ultimate goal of improving TB diagnostics, prevention, and treatment and ending morbidity and mortality from TB world-wide.

总体摘要：我们提议建立一个三机构结核病 (TB) 研究推进中心 （TRAC）在威尔康奈尔医学院、纪念斯隆-凯特琳癌症中心和洛克菲勒大学。这 纽约市的三所院校 (Tri-I) 校园内的三所院校彼此相邻。目的 拟议的 Tri-I TRAC 的目的是汇集由 20 名高级 TB 组成的优秀团队的专业知识和资源 三个机构的研究人员扩大结核病研究领域的研究人员数量，并 促进创新的多学科结核病研究。资深调查员拥有多元化的专业知识 涵盖生物化学、基础微生物学、分枝杆菌遗传学、人类遗传学和免疫学、药物 发现、国际临床试验和实施科学。主要重点将是支持新 研究者 (NI)，我们将其定义为寻求研究的高级博士后研究员或初级教员 学术生涯，尚未获得 R01。我们还将招募结核病新手 (N2TB) 调查员， 他们是其他科学学科中经验丰富的 R01 研究者，他们将自己的专业知识用于结核病研究。这 TRAC 将有四个核心。行政核心将提供领导、财务监督、 沟通和计划评估。发展核心将资助 6 个发展项目奖 每年每人 50,000 美元支持 NI 和 N2TB 调查人员。威尔康奈尔大学的机构支持 医学界每年将资助其中两个奖项，这些奖项将指定给代表性不足的少数族裔 和女科学家。临床核心将建立在主要在海地和 也在坦桑尼亚。基础科学和临床科学核心课程将为 NI 和 N2TB 接受者提供发育科学课程 项目奖励结核病研究特有的指导、技术专长和科学资源，包括 获得结核病动物模型、转基因分枝杆菌库和生物库临床样本。这 基础和临床科学核心还将促进高级结核病患者之间的技术和资源共享 研究人员以启动新的协作转化结核病研究。其他活动包括 年度研讨会、技术研讨会以及前往国际结核病临床地点的旅行将加强 培养新的结核病研究者并创造有利于多学科合作的环境。 不会与其他 NIH 研究资助、中心或机构核心重叠。 TRAC 将利用 这些现有资源并协同扩大结核病调查人员的数量并培育新的创新 合作线。我们 5 年内的目标是让 25 名 NI 成功竞争结核病相关的 NIH R01 过渡到独立并吸引至少 5 名 N2TB 研究者进入结核病科学领域。一半将是 女性和至少 20% 代表性不足的少数族裔。我们还将启动新的合作领域 转化研究，解决结核病科学领域的五个 NIAID 优先事项，最终目标是改善结核病 诊断、预防和治疗，并消除全世界结核病的发病率和死亡率。